Challenges and misconceptions in the aetiology and management of atrial fibrillation-related strokes

Area of Science:

• Cardiology
• Neurology
• Primary Care Medicine

Background:

• Atrial fibrillation (AF) significantly increases stroke risk, necessitating effective prevention strategies.
• Vitamin K antagonists (VKAs) have historically been primary stroke prevention agents in AF.
• Direct oral anticoagulants (DOACs) represent a newer class of anticoagulants with distinct profiles.

Purpose of the Study:

• To address dilemmas faced by primary care clinicians in managing stroke and transient ischaemic attack (TIA) in AF patients.
• To clarify stroke classification, AF-related stroke types, prognosis, and early management strategies.
• To discuss therapeutic options for anticoagulant-associated intracerebral hemorrhage and dispel misconceptions among non-stroke specialists.

Main Methods:

• Narrative review of current literature and clinical guidelines.
• Discussion of stroke classification and AF-related stroke characteristics.
• Analysis of anticoagulation strategies (VKAs vs. DOACs) for stroke prevention in AF.

Main Results:

• Stroke is a major complication of AF, with both ischaemic and haemorrhagic types.
• DOACs offer an alternative to VKAs, each with specific advantages and disadvantages.
• Misconceptions among non-specialists can lead to suboptimal stroke prevention and management in AF patients.

Conclusions:

• Effective stroke prevention and management in AF require a clear understanding of stroke types, prognoses, and treatment options.
• Primary care clinicians play a crucial role in navigating anticoagulation choices and managing AF-related neurological events.
• Addressing misconceptions is vital for optimizing stroke prevention and care in the AF population.